T he differentiation of naive CD4 + helper T cells into the various lineages of effector populations drives immune responses to pathogens, or to self antigens, in the case of autoimmune disorders. Proinflammatory helper T cell effector lineages are defined by the secretion of characteristic profiles of cytokines: interferon-γ is secreted by T helper type 1 cells (T H 1 cells), and interleukin 17 (IL-17) is secreted by T H -17 cells. Both of these populations of helper T cells, along with CD25 + Foxp3 + regulatory T cells, control tissue destruction in multiple sclerosis, an autoimmune disorder in which the myelin sheaths of central nervous system (CNS) neurons are destroyed by inflammatory and degenerative processes. Considerable effort has been devoted to elucidating the mechanisms by which autoimmunity and helper T cell differentiation are regulated, and studies providing descriptions of several key cyto kines, signaling molecules and transcription factors have paved the way for the design of T H -17 cellspecific diagnostic and therapeutic agents. In this issue of Nature Immunology, Du and colleagues 1 establish a role for microRNA (miRNA) particles in the regulation of T H -17 differentiation and autoimmune disease. Their work positively associates the amount of the miRNA species miR-326 with active disease relapses in patients with multiple sclerosis and uses overexpression and interMicroRNA-managing the T H -17 inflammatory response
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The differentiation of interleukin 17-producing helper T cells is controlled by a complex network of cytokines, signaling pathways and transcription factors. Regulation by microRNA particles can now be added to this list.
ference tools to manipulate the amount of miR-326 in the experimental autoimmune encephalomyelitis (EAE) animal model of multiple sclerosis, in which T H -17 cells have a critical pathologic role 1, 2 . They show that forced expression of miR-326 worsens EAE symptoms and enhances T H -17 differentiation, whereas neutralization of miR-326 improves clinical outcome and impairs T H -17 differentiation. Finally, they demonstrate that miR-326 binds to and prevents translation of Ets-1 mRNA, a known inhibitor of T H -17 differentiation (Fig. 1) .
The miRNAs are short molecules of RNA (approximately 22 nucleotides in length) that are transcribed from noncoding regions of the genome and have considerable secondary structure 3 . The nucleases Drosha, Pasha and Dicer are involved in processing the miRNA from a hairpin configuration into a short RNA duplex and finally into a singlestranded miRNA, which is then loaded into the RNA-induced silencing complex. This complex and its associated miRNA then bind complementary sequences in 3′ untranslated regions (called 'seed regions') of mRNA species and inhibit their translation by two distinct mechanisms: degradation of the message by the RNA-induced silencing complex protein argonaute; and prevention of ribosomal binding and translation initiation 3 . Notably, Du et al. show that miR-326 interferes with Ets-1 synthesis mainly by inhibiting translation initiation, as miR-326 overexpression decreases Ets-1 protein but not the amount of Ets-1 mRNA 1 .
The differentiation of T H -17 cells from naive precursors is governed by a complex network of cytokines, signaling pathways and transcription factors. It is well accepted that signaling through the receptors for IL-6 and transforming growth factor-β (TGF-β) by STAT3 and presumably through Smad 1 . Although it has been previously shown that miRNAs can affect developmental outcomes in thymic T cell precursors, influence regulatory T cell development and affect the production of antibodies to thymus-dependent antigens, this is the first demonstration that a specific miRNA directly influences the T H -17 effector subset and contributes to autoimmune pathology. Work continuing to catalog miRNA species and associate them with various helper T cell lineages, immune functions and autoimmune pathology would be of great interest.
An intriguing observation made in this paper is that miR-326 interferes with the protein synthesis of one T H -17 antagonist (Ets-1) but not another (Foxp3; Fig. 1 ). It will therefore be a challenge to determine if miR-326 contributes to the commitment of naive precursors to the T H -17 lineage, as does IL-6-TGF-β, or if it functions to stabilize helper T cells that are already producing IL-17 in the manner of IL-23-IL-21. Signals from TGF-β, IL-2R and the T cell antigen receptor converge to upregulate Foxp3 expression and initiate the differentiation of regulatory T cells, and STAT5 and Foxp3 discourage T H -17 differentiation by interfering with RORγ t expression or function and thus preventing Il17 transactivation 4 . Because of the involvement of Ets-1 in IL-2 synthesis and IL-2R signaling, we speculate that miR-326 functions to regulate IL-2R signals through Ets-1 while allowing TGF-β signals to continue unperturbed. This may allow TGF-β signaling to contribute to the expression of both Foxp3 and IL-17, which is consistent with reports indicating that both Foxp3 and IL-17 are expressed at early times in T H -17 differentiation, when the naive precursors show considerable plasticity 5, 6 . If this is true, then miR-326 serves to uncouple TGF-β signaling from IL-2R signals and promote T H -17 differentiation over regulatory T cell differentiation at an early developmental stage. Regardless of whether it is true, because of the presence of the TGF-β-induced Foxp3, IL-6 receptor signals transduced by STAT3 will still be needed to antagonize the differentiation of regulatory T cells and commit naive precursors to the T H -17 lineage. In fact, data presented by Du and colleagues support this idea, as interference with miR-326 with a 'sponge' vector decreases but does not completely ablate IL-17 synthesis 1 . It is therefore probable that miR-326 contributes to T H -17 differentiation but is not required for lineage commitment. It has been shown that Ets-1 regulates IL-2 mRNA expression but not the amount of RORγt transcript. Upregulation of RORγt transcripts by forced expression of miR-326 suggests that in addition to Ets-1, miR-326 may also perturb a potential inhibitor of Rorc, the gene encoding RORγt. Further work describing the precise role of this miRNA relative to that of the other molecules known to be involved in T H -17 differentiation is therefore of considerable interest.
There are two additional exciting suggestions that result from the paper from Du et al.: the interpretation of data previously generated by knockout and overexpression models and biomarker discovery. This miRNA species is encoded by an untranslated region of the gene encoding β-arrestin-1, and both β-arrestin-1 and miR-326 are positively associated with the development of CNS autoimmunity 1, 7 . Although the mechanistic contributions of β-arrestin-1 have been clearly demonstrated, it is possible that β-arrestin-deficient mice also lack miR-326. Knocking out both a gene and an embedded miRNA-coding sequence that both mediate autoimmune disease could potentially affect the interpretation of disease outcome and lead to the improper assignment of an role to the gene being studied. Going forward, it will be of importance to carefully examine candidate genes for miRNA sequences before performing knockout studies.
The second exciting possibility this work opens is the authors' proposed use of miR-326 as a biomarker for the development or relapse of multiple sclerosis. Such a diagnostic tool would be of tremendous clinical importance in multiple sclerosis, as tissue samples of the target organ (the CNS or cerebrospinal fluid) are difficult or impossible to obtain. In contrast, miR-326 can be detected in easily accessible circulating T cells. Studies aiming to confirm miR-326 as a biomarker in multiple sclerosis should be prioritized.
The finding that miRNAs can directly regulate T H -17 differentiation and contribute to autoimmune pathology is a substantial advance; however, several outstanding questions remain. Although the authors' claim that miR-326 can serve as a possible diagnostic marker is well supported, the therapeutic potential of this target is less clear. It would be much more clinically relevant to see the outcome of treating animals with the miR-326 sponge vector after they present with clinical symptoms of EAE. As previous studies have shown that epitope spreading in the SJL/J mouse model of relapsing EAE involves the activation of T H -17 cells specific for endogenously released myelin epitopes mainly in the inflamed CNS 8, 9 , determining the effects of treatment with the miR-326 sponge vector during disease remission on incidence of disease relapses would be extremely interesting. Furthermore, if miRNAs are to be seriously considered as therapeutic targets in autoimmune disorders, the development of an efficient nonviral delivery method is of paramount importance, particularly if activation of T cells to spread epitopes before disease relapse occurs mainly in the CNS. Several studies involving the delivery of small interfering RNA molecules by biopolymer microparticles or nanoparticles have been published 10 , and phase I clinical trial are active or in the recruitment stage (NCT00689065 and NCT00882180). If these obstacles are overcome, a third concern involves the proper timing of any therapeutic designed to target the T H -17 lineage. The T H 1 lineage and chemokine receptor-mediated events can initiate EAE by facilitating the entry of T H -17 cells into the CNS 11, 12 . Furthermore, the ratio of T H N E w S A N d v I E w S of disease 13 . It is therefore possible that therapeutics that target only the T H -17 lineage may be effective only at certain times or in certain disease conditions. The most successful treatment strategies will probably target both the T H 1 and T H -17 cell effector subsets in an autoantigen-specific manner. Collectively, the data in Du's publication establish a role for miR-326 as a regulator of T H -17 differentiation and the development of autoimmune disease while identifying a promising target for use as a diagnostic or therapeutic biomarker. Furthermore, this paper lays a fertile groundwork for future research into the precise roles of miRNAs in helper T cell differentiation, cytokine receptor signaling and transcription factor function.
